Patents by Inventor Javier Ganz

Javier Ganz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PERK inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins
    Patent number: 11104651
    Abstract: Compounds represented by Formula I are disclosed herein, wherein R, Ra and R1-R14 are as defined herein. Further disclosed are uses and methods utilizing said compounds for use in inhibiting an activity of PERK, and in treating a disease or disorder associated with aggregation-prone proteins, a disease or disorder in which downregulating an unfolded protein response is beneficial, and/or Huntington's disease.
    Type: Grant
    Filed: July 5, 2020
    Date of Patent: August 31, 2021
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Gerardo Zelmar Lederkremer, Julia Leitman, Hagit Eiger, Daniel Offen, Javier Ganz, Moshe Portnoy
  • PERK INHIBITORS AND USES THEREOF IN TREATING DISEASES ASSOCIATED WITH AGGREGATION-PRONE PROTEINS
    Publication number: 20200331865
    Abstract: Compounds represented by Formula I are disclosed herein, wherein R, Ra and R1-R14 are as defined herein. Further disclosed are uses and methods utilizing said compounds for use in inhibiting an activity of PERK, and in treating a disease or disorder associated with aggregation-prone proteins, a disease or disorder in which downregulating an unfolded protein response is beneficial, and/or Huntington's disease.
    Type: Application
    Filed: July 5, 2020
    Publication date: October 22, 2020
    Applicant: Ramot at Tel-Aviv University Ltd.
    Inventors: Gerardo Zelmar LEDERKREMER, Julia LEITMAN, Hagit EIGER, Daniel OFFEN, Javier GANZ, Moshe PORTNOY
  • Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins
    Patent number: 10723706
    Abstract: Compounds represented by Formula I are disclosed herein, wherein R, Ra and R1-R14 are as defined herein. Further disclosed are uses and methods utilizing said compounds for use in inhibiting an activity of PERK, and in treating a disease or disorder associated with aggregation-prone proteins, a disease or disorder in which downregulating an unfolded protein response is beneficial, and/or Huntington's disease.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: July 28, 2020
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Gerardo Zelmar Lederkremer, Julia Leitman, Hagit Eiger, Daniel Offen, Javier Ganz, Moshe Portnoy
  • PERK INHIBITORS AND USES THEREOF IN TREATING DISEASES ASSOCIATED WITH AGGREGATION-PRONE PROTEINS
    Publication number: 20190010130
    Abstract: Compounds represented by Formula I are disclosed herein, wherein R, Ra and R1-R14 are as defined herein. Further disclosed are uses and methods utilizing said compounds for use in inhibiting an activity of PERK, and in treating a disease or disorder associated with aggregation-prone proteins, a disease or disorder in which downregulating an unfolded protein response is beneficial, and/or Huntington's disease.
    Type: Application
    Filed: June 13, 2017
    Publication date: January 10, 2019
    Applicant: Ramot at Tel-Aviv University Ltd.
    Inventors: Gerardo Zelmar LEDERKREMER, Julia LEITMAN, Hagit EIGER, Daniel OFFEN, Javier GANZ, MOshe PORTNOY
  • SCAFFOLD-SEEDED ORAL MUCOSA STEM CELLS
    Publication number: 20180008648
    Abstract: A method of treating a spinal cord injury in a subject in need thereof is disclosed. The method comprises implanting a scaffold into the spinal cord of a subject, wherein the scaffold is seeded with oral mucosa stem cells (OMSC) and/or cells that have been ex vivo differentiated from said OMSCs, thereby treating the spinal cord injury.
    Type: Application
    Filed: January 31, 2016
    Publication date: January 11, 2018
    Inventors: Shulamit LEVENBERG, Sandu PITARU, Daniel OFFEN, Javier Ganz, Sivan Ida COHEN-MATSLIAH, Erez SHOR
  • Stem cell-derived neural cells for cell therapy in neurological disorders
    Patent number: 9717761
    Abstract: The present invention provides methods and uses of neural cells differentiated from adult stem cells of the oral mucosa for cell therapy of neurological and psychiatric diseases and disorders. Methods for direction of differentiation of oral mucosal stem cells into neuronal or neuron supporting cells are also provided.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: August 1, 2017
    Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Sandu Pitaru, Javier Ganz, Daniel Offen, Eldad Melamed
  • STEM CELL-DERIVED NEURAL CELLS FOR CELL THERAPY IN NEUROLOGICAL DISORDERS
    Publication number: 20140335059
    Abstract: The present invention provides methods and uses of neural cells differentiated from adult stem cells of the oral mucosa for cell therapy of neurological and psychiatric diseases and disorders. Methods for direction of differentiation of oral mucosal stem cells into neuronal or neuron supporting cells are also provided.
    Type: Application
    Filed: November 21, 2012
    Publication date: November 13, 2014
    Inventors: Sandu Pitaru, Javier Ganz, Daniel Offen, Eldad Melamed
  • ISOLATION AND USE OF A NEW TYPE OF GLIAL CELL WITH NEUROTOXIC POTENTIAL
    Publication number: 20130058918
    Abstract: The present invention provides for an isolated population of aberrant astrocytes, methods of isolating the aberrant astrocytes, methods of diagnosing neurodegenerative diseases, methods of drug screening using the aberrant astrocytes, and treatment methods targeting function, activity, and signaling associated with aberrant astrocytes.
    Type: Application
    Filed: May 11, 2011
    Publication date: March 7, 2013
    Applicant: Cedars-Sinai Medical Center
    Inventors: Luis Barbeito, Pablo Diaz-Amarilla, Silvia Olivera, Javier Ganz